Kura Oncology Inc (NASDAQ:KURA) – Oppenheimer raised their FY2019 earnings estimates for shares of Kura Oncology in a research note issued on Monday, November 5th. Oppenheimer analyst L. Cann now expects that the company will post earnings of ($2.73) per share for the year, up from their previous forecast of ($2.95). Oppenheimer also issued estimates for Kura Oncology’s FY2022 earnings at $12.98 EPS.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.01.
KURA stock opened at $11.91 on Thursday. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $24.02. The company has a quick ratio of 10.22, a current ratio of 14.76 and a debt-to-equity ratio of 0.02.
Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. bought a new position in Kura Oncology in the 2nd quarter valued at $2,412,000. Swiss National Bank bought a new position in Kura Oncology in the 2nd quarter valued at $768,000. Prosight Management LP bought a new position in Kura Oncology in the 2nd quarter valued at $5,240,000. Sio Capital Management LLC boosted its position in Kura Oncology by 27.4% in the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock valued at $15,244,000 after buying an additional 180,193 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Kura Oncology by 25.5% in the 2nd quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after buying an additional 406,963 shares during the last quarter. Hedge funds and other institutional investors own 77.28% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.